Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Addex Therapeutics Ltd
  6. News
  7. Summary
    ADXN   CH0029850754


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Press Release : Addex to Present at the Swiss Biotech Day

09/02/2021 | 01:00am EDT

Geneva, Switzerland, September 2, 2021 -- Addex https://www.globenewswire.com/Tracker?data=-raRRcjNKF8qH3q5JxV3eb6L-Wj-jLdaYTOU_vXMoDAYuwnHkTYucqJG3yQ5x3fhRWjot90te-VJE2mp78KRkAZqPDZLvAeg68iKukbvfDE= Therapeutics https://www.globenewswire.com/Tracker?data=iMa6uU0l8wCm2yMrb3UZbOLX0RdesX4AvBGKebK0UIXFemkRmirBv9UI7LJpzapkRxng0tu7gFkjq7l1iC24b8U4GNwTvYAsz9ZPZQieaYw= (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present a corporate overview at the Swiss Biotech Day https://www.globenewswire.com/Tracker?data=c4xqVjko96UK8glZ_u9F02exEm3KY52iRhCZcuKQ-tdQgECte5YEE7N-brgfIIEr9Er5VQmMs7qpACGv1CF79OSRHIoI_JssS_D-dr93UV0= , held September 7, 2021 at the Congress Center Basel, Messeplatz 21, 4058 Basel, Switzerland. Mr. Dyer's presentation is scheduled for 13:15 in room Montreal.

If you would like to schedule a meeting with Mr. Dyer, please send a request to: investors@addextherapeutics.com https://www.globenewswire.com/Tracker?data=MHOUBW2x-drHwLEk5_IEnsbObwrJi0WnTPWmCDiTSI8EP8bwALI0Xb2-tcjjKwsaFajFKs3amKB7FeUMGQ3bcbbOsBnGdtTvDLgEcJiMHLhPvfruJaqoGGUwhfosEkIn .

About Addex Therapeutics

Addex Therapeutics https://www.globenewswire.com/Tracker?data=-raRRcjNKF8qH3q5JxV3eVnasajHCSwIPnwn6xsOF6foX0RYNx4XYOyxqDKnmRgfqDnRfgmt3swQxBmeDKfVhM7lySqxBufEvvMVi0qrq1g= is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is in a pivotal registration clinical trial for Parkinson's disease levodopa induced dyskinesia (PD-LID). Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in Q3 2021. Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is in a Phase 2a proof of concept clinical trial for the treatment of epilepsy. Indivior PLC has licensed Addex's GABA(B) PAM program for the development of drug candidates with a focus in addiction. Preclinical programs ongoing with Addex include GABA(B) PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson's disease and mGlu3 PAM for neurodegenerative disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol "ADXN" on each exchange.


Tim Dyer                   Mike Sinclair              James Carbonara 
 Chief Executive Officer    Partner, Halsin Partners   Hayden IR 
 Telephone: +41 22 884 15   +44 (0)20 7318 2955        (646)-755-7412 
 55                         msinclair@halsin.com       james@haydenir.com 

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks, ' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions securityholders and prospective securityholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

(END) Dow Jones Newswires

September 02, 2021 01:00 ET (05:00 GMT)

10/06PRESS RELEASE : Addex to Present at the Investors' Day hosted by Voxia Communication
10/06ADDEX THERAPEUTICS : to Present at the Investors' Day hosted by Voxia Communication
10/06ADDEX THERAPEUTICS : Addex to Present at the Investors' Day hosted by Voxia Communication
10/06Addex to Present at the Investors' Day hosted by Voxia Communication
10/04PRESS RELEASE : Addex to Present at the 10th -2-
10/04PRESS RELEASE : Addex to Present at the 10th International Meeting on Metabotropic Glutama..
10/04Addex to Present at the 10th International Meeting on Metabotropic Glutamate Receptors
09/29ADDEX THERAPEUTICS : Type of dystonia characterized by involuntary spasms of the eyelid mu..
09/29ADDEX THERAPEUTICS : Commences Mid-Stage Trial of Dipraglurant in Blepharospasm
09/29ADDEX THERAPEUTICS : Starts Mid-Stage Trial For Eyelid Muscles Spasm Drug
More news
Analyst Recommendations on ADDEX THERAPEUTICS LTD
More recommendations
Sales 2021 2,35 M 2,57 M 2,57 M
Net income 2021 -16,5 M -18,0 M -18,0 M
Net Debt 2021 5,28 M 5,76 M 5,76 M
P/E ratio 2021 -2,60x
Yield 2021 -
Capitalization 42,6 M 46,5 M 46,5 M
EV / Sales 2021 20,4x
EV / Sales 2022 35,6x
Nbr of Employees 27
Free-Float 65,1%
Duration : Period :
Addex Therapeutics Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADDEX THERAPEUTICS LTD
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 1,25 CHF
Average target price 25,72 CHF
Spread / Average Target 1 958%
EPS Revisions
Managers and Directors
Timothy Dyer Chief Executive Officer & Director
Lénaic Teyssédou Head-Finance
Vincent M. Lawton Chairman
Roger G. Mills Director & Chief Medical Officer
Raymond George Hill Director
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.225.04%137 066
LONZA GROUP AG32.03%60 786
SEAGEN INC.-0.71%31 638
CELLTRION, INC.-39.42%25 233